BAU Journal - Health and Wellbeing
Volume 1 Issue 3
SPECIAL ISSUE
Urban Health & Wellbeing Building Collaborative
Intelligence for Better Lives in Cities

Article 49

ISSN: 2617-1635
October 2018

THE CLINICAL BENEFIT OF SERUM PROCALCITONIN LEVELAS
COMPARED TO BISAP SCORING SYSTEM FOR PREDICTINGTHE
SEVERITY AND PROGNOSIS OF ACUTE PANCREATITIS
OMAR MASRI Division of Gastroenterology, Department of Internal Medicine,
Makassed General Hospital, Beirut, Lebanon, omar_masri1@hotmail.com

NADIA JRADI Senior Lecturer of Pediatrics, Department of Clinical Science, Faculty of Medicine
Beirut Arab University, Lebanon, n.jradi@bau.edu.lb

MOHAMED KASSEM
Makassed General Hospital, Beirut, Lebanon, kassemm2@yahoo.com

Follow this and additional works at: https://digitalcommons.bau.edu.lb/hwbjournal
Part of the Architecture Commons, Business Commons, Life Sciences Commons, and the Medicine
and Health Sciences Commons

Recommended Citation
MASRI, OMAR Division of Gastroenterology, Department of Internal Medicine,; JRADI, NADIA Senior
Lecturer of Pediatrics, Department of Clinical Science, Faculty of Medicine; and KASSEM, MOHAMED
(2018) "THE CLINICAL BENEFIT OF SERUM PROCALCITONIN LEVELAS COMPARED TO BISAP SCORING
SYSTEM FOR PREDICTINGTHE SEVERITY AND PROGNOSIS OF ACUTE PANCREATITIS," BAU Journal Health and Wellbeing: Vol. 1 : Iss. 3 , Article 49.
Available at: https://digitalcommons.bau.edu.lb/hwbjournal/vol1/iss3/49

This Article is brought to you for free and open access by Digital Commons @ BAU. It has been accepted for
inclusion in BAU Journal - Health and Wellbeing by an authorized editor of Digital Commons @ BAU. For more
information, please contact ibtihal@bau.edu.lb.

THE CLINICAL BENEFIT OF SERUM PROCALCITONIN LEVELAS COMPARED TO
BISAP SCORING SYSTEM FOR PREDICTINGTHE SEVERITY AND PROGNOSIS OF
ACUTE PANCREATITIS
Abstract
Background: Early accurate severity assessment of patients with acute pancreatitis (AP) is cruicial to
decide on the acute management and predict outcomes and prognosis.This is done through multiple
scoring systems of which serum procalcitonin (PCT) and BISAP has shown promising results.
However,data comparing these methods is still conflicting. Objectives: we aim to assess the role of
PCT as a sole indicator and compare it to BISAP in determining severity and prognosis of AP. Methods:
Retrospective chart review of all AP cases between June 2012 and February 2017 at Makassed General
Hospital, with at least one reading of PCT documented in records. Data regarding patients’ demographics
and outcomes were collected. Procalcitonin levels and trends were compared to severity classes and
BISAP scores regarding various outcomes of AP. Results: Forty-four patients met our inclusion criteria.
Based on the revised Atlanta classification, 26 patients had mild, four moderate and 14 severe AP. Mean
serum PCT levels were found to correlate with severity classes (1.28 with mild versus 4.81 with moderatesevere AP; P < 0 .0001). This was even more prominent on follow-up testing after 48hours (1.67 vs 12.89
respectively; P=0.01). This proportional relation was again noted with BISAP scores of 0,1 and 2 where the
mean PCT was 0.1,5.0 and 19.1 respectively. A trend of decrease in serial PCT was also noted with mild as
compared to a trend of rising PCT in moderate-severe AP. Conclusion: Initial and serial PCT levels directly
correlated with disease severity and might offer significant additional prognostic value in AP.
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ABSTRACT: Background: Early accurate severity assessment of patients with acute
pancreatitis (AP) is cruicial to decide on the acute management and predict outcomes and
prognosis.This is done through multiple scoring systems of which serum procalcitonin (PCT)
and BISAP has shown promising results. However,data comparing these methods is still
conflicting. Objectives: we aim to assess the role of PCT as a sole indicator and compare it
to BISAP in determining severity and prognosis of AP. Methods: Retrospective chart review
of all AP cases between June2012 and February2017 at Makassed General Hospital, with at
least one reading of PCT documented in records. Data regarding patients’ demographics
and outcomes were collected. Procalcitonin levels and trends were compared to severity
classes and BISAP scores regarding various outcomes of AP. Results: Forty-four patients
met our inclusion criteria. Based on the revised Atlanta classification, 26 patients had mild,
four moderate and 14 severe AP. Mean serum PCT levels were found to correlate with
severity classes (1.28 with mild versus 4.81 with moderate-severe AP; P<0.0001). This was
even more prominent on follow-up testing after 48hours (1.67 vs 12.89 respectively;P=0.01).
This proportional relation was again noted with BISAP scores of 0,1 and 2 where the mean
PCT was 0.1,5.0 and 19.1 respectively. A trend of decrease in serial PCT was also noted with
mild as compared to a trend of rising PCT in moderate-severe AP.
Conclusion: Initial and serial PCT levels directly correlated with disease severity and might
offer significant additional prognostic value in AP.
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1. INTRODUCTION
Acute pancreatitis (AP) is an inflammatory condition of the pancreas characterized by severe
Characteristic epigastria pain along with an elevation of pancreatic enzymes, namely amylase and lipase
(Kusske,1996) .Approximately 20 percent of cases develop moderately severe or severe acute pancreatitis,
characterized by local complications or organ failure. Expectedly, patients with severe or necrotizing
pancreatitis had a significantly higher mortality when compared to patients with mild interstitial pancreatitis
(17 versus 3 percent) (Banks, 2006). Tremendous research efforts were put into assessing the severity and
prognostic factors of AP in order to help in the management as well as to determine the best in-hospital setting
for such patients. The revised Atlanta classification system stratifies patients to mild, moderate and severe
based on the presence or absence of local or systemic complications and of organ failure (Lee, 2016).Different
predictive models and scoring systems were developed and validated over the past few decades to aid in
prognostication, including the APACHE II and the Ranson’s criteria were among the early scoring systems
that showed good accuracy inpredicting the severity of pancreatitis; however, they were limited by their
complicated multiple parameters and the time delay needed to fulfill its criteria (Yang, 2014). More recently,
the bedside index of severity in acute pancreatitis (BISAP) –a more simple and practical score- was tested and
validated for this purpose and showed similar sensitivity and predictive value when compared to the other
previous scores (Papachristou, 2010).
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Aiming at finding better and simpler prognostic indicator, small studies addressed the utility of serum
procalcitonin (PCT)levels in determining outcomes of patients with AP. PCT is the inactive pro-peptide of the
hormone calcitonin, which is involved in calcium homeostasis. The increased serum PCT correlates closely
with the inflammatory response of a host to microbial infections, namely bacterial and fungal infections
(Villatoro, 2010). In patients who suffer from acute pancreatitis, PCT has been shown to predict the
development of infected pancreatic necrosis (Al-Nawas, 1996) . In addition, it was suggested that PCT might
be an early predictor of severity and organ failure in patients with AP (Modrau, 2005). The significance of
measuring the PCT level in the assessment of the severity of acute pancreatitis as well as predicting the risk of
developing infected pancreatic necrosis was tested inseveral studies. Systematic reviews of these studies
yielded contradicting results. The most recent one published in 2009 suggested a valuable role of serum PCT
in predicting the severity of acute pancreatitis and the risk of developing infected pancreatic necrosis (Mofidi,
2009). The sensitivity and specificity of PCT for predicting the development of severe AP were 0.72 and 0.86,
respectively. Moreover, the sensitivity and specificity of PCT for prediction of infected pancreatic necrosis
were 0.80 and 0.91 (95% CI = 13.8--58.3) (Al-Nawas, 1996) .When comparing PCT to BISAP score, data were
also contradicting. A Korean study in 2013 compared BISAP to other scoring systems including PCT, showed
that BISAP was more accurate than PCT (BISAP 84% accurate and PCT 76%) (Kim, 2013). However, data is
still insufficient.
In this study, we aim to assess the role of procalcitonin and to compare it to BISAP in determining the
disease severity and prognosis according to revised Atlanta Classification for severity of acute pancreatitis
2. MATERIALS AND METHODS
2.1 Setting and Data Collection
This is a retrospective chart review of all patients diagnosed with acute pancreatitis who were
admitted to Makassed General Hospital (MGH) between June 2012 (the date were PCT was first
introduced to our laboratory) and February 2017. Data were retrieved from the patients’ electronic
medical records. Only patients above the age of 18 at diagnosis, with at least one reading of Procalcitonin
in their charts and with clear documentation sufficient for the calculation of BISAP score were selected
for data collection and comparison. Exclusion criteria included patients with chronic pancreatitis,
preceding active sepsis from a definitive focus other than AP and those with incomplete chart
documentation. Datathat were collected from the selected charts included: Patients’ demographics,
associated comorbidities, etiology of AP, results of any imaging performed, the presence of any local
complications or the occurrence of any organ failure (needed for the revised atlanta criteria), the criteria
for calculating the BISAP score, PCT readings, duration of hospital stay, the use of antibiotics, the need
for intervention, and mortality. PCT levels were measured using an immunoturbidimetry method (Roche
Diagnostics, Indianapolis, Ind) and an enzyme-linked fluorescent assay (bioMerieux, France),
respectively.
Patients were first categorized into mild, moderate and severe AP based on the criteria for the revised
Atlanta classification. The BISAP score and the initial as well as the other PCT readings were then plotted
and comparison was performed to show the concordance between these three predictive modelswith
respect to the various outcomes of AP.
Definitions
Revised Atlanta classification system: divides patients with AP into a. mild AP, characterized
by the absence of any organ failure and local or systemic complications. (ii) Moderately severe AP,
characterized by transient organ failure (resolving within 48 hours) and/or local or systemic
complications without persistent organ failure. (iii) Severe acute pancreatitis, characterized by persistent
organ failure that may involve one or multiple organs
BISAP “Bedside Index for Severity in Acute Pancreatitis”: is a score that has been developed to
identify patients at high risk for mortality or severe disease early during the course of acute pancreatitis.
It gives one point to each of the following five criteria: Serum BUN of more than 25mg/dl, Impaired
mental status, presence of systemic immune response syndrome (SIRS), age > 60 years, and the
presence of pleural effusion.
Procalcitonin: A biochemical marker (a peptide precursor of hormone calcitonin) composed of
116amino acids and produced by cells of thyroid, lungs, and intestines. Its level rise in bacterial
infections, not in viral or non-infectious inflammations. It is used as a marker for sepsis with
sensitivity (85%) and specificity (91%) for differentiating patients with systemic inflammatory response
syndrome (SIRS) from those with sepsis (Gurda-Duda, 20
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2.2 Statistical analysis
The Statistical Package for Social Sciences (SPSS, version 21) program was used for data entry,
management, and analyses. A p-value of <0.05 is used to indicate statistical significance.Categorical
variables are presented as number and percent, whereas continuous variables are presented as mean and
standard deviation. Bivariate analysis was carried out by using the chi square for comparing categorical
variables, whereas continuous ones were compared using the Student's t-test.
3. RESULTS:
The total number of patients who met the study’s inclusion criteria was 44 patients. Twenty-six patients
(59%) were found to have mild APaccording to the revised Atlanta classification, whereas 4 patients (9%) had
moderately severe AP and 14 patients (32%) had severe AP. Because of the small number of patients with
moderate AP, and because this category shares some similar characteristics with patients having severe AP,
these two groups were combined together under “moderate-severe AP” category, and were compared to
patients with “mild AP”.
The two groups were similar with respect to baseline characteristics including age and gender (Table 1).
Table 1: Characteristics of 44 Patients with Acute Pancreatitis
Mild
N=26
Age, mean (±SD)
Gender
Male
Female
Etiology
Alcoholic

59.50 (±20.67)
15 (57.7%)
11 (42.3%)

Pancreatitis
Moderate-Severe
N=18
61.28 (±20.97)

P-value
0.77

6 (33.3%)
12 (66.7%)

0.14

2 (7.7%)

1 (5.6%)

1.00

Biliary

11 (42.3%)

7 (38.9%)

0.75

Hypertriglyceridemia

3 (11.5%)

3 (16.7%)

0.68

0 (0.0%)
3
1 (5.6%)
11 (42.3%)

0 (0.0%)
1 (5.6%)
1 (5.6%)
7 (38.9%)

NA
NS

ICU admission

0 (0.0%)

13 (72.2%)

Mechanical ventilation

0 (0.0%)

9 (50.0%)

<0.0001

Necrosis

0 (0.0%)

1 (5.6%)

0.41

20 (76.9%)
8 (30.8%)

18 (100.0%)
3 (16.7%)

0.07
0.48

Hypercalcemia
Drug induced
Post-ERCP
Other

1.00

Outcome

Antibiotic use
Intervention
Mortality
Duration of hospitalization, mean (±SD)

0 (0.0%)

6 (33.3%)

6.69 (±3.80)

17.11 (±9.40)

<0.0001

0.003
<0.0001

The most common etiology for AP was biliary(40.9%). Other causes included alcohol (6.6%), and
hypertriglyceridemia (14.1%), drug induced (9%) and post ERCP pancreatitis (4.5%). Expectedly, patients
with moderate-severe AP had worse outcomes with 13 cases requiring ICU admissions (72.2%) of which 9
needed mechanical ventilation (50%) and a total of 6 in-hospital mortalities (33.3%) as compared to none in
the mild AP group. Both groups had similar surgical intervention (mainly cholecystectomy) and antibiotics use
rates.
Moreover, the hospitalization duration was significantly higher (mean =17.11 ±9.40) among
moderate-severe pancreatitis patients.
Both BISAP score and PCT levels were significantly higher in moderate-severe acute pancreatitis patients
when compared to those of mild disease (p<0.0001) (Table2).
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Table 2: Correlation between revised Atlanta classification and the mean BISAP score and mean PCT levels.

Pancreatitis
Mild
N=26

ModerateSevere
N=18

Pvalue

Scoring/biochemical markers
BISAP score, mean (±SD)

1.12 (±1.18)

2.89 (±1.18)

<0.00
01

Procalcitonin (PCT1), mean (±SD)

1.28 (±3.73)

4.81 (±6.05)

<0.00
01

Procalcitonin (PCT2), mean (±SD)

1.67 (±4.61)

12.89 (±26.28)

0.
01

Procalcitonin (PCT1+PCT2), mean (±SD)

2.05 (±6.71)

14.84 (±25.92)

<0.00
01

Interestingly, there was a clear and linear quantitative correlation between the mean PCT level upon
admission and after 48 hours with the severity of AP and with the BISAP score. Even when we subdivided the
patients into mild , moderate and severe categories, the mean PCT level seemed to proportionally rise with the
increase in the severity, from 1.27 in patients with mild, to 2.20 in moderate and 5.56 in severe AP. Fifty
percent of patients with moderate-severe AP had a PCT level above the cutoff of 2 as compared to only 7% in
patients with mild AP. Moreover, there was a greater tendency of having a rising PCT level by more than 50%
after 48 hours in severe cases (30%) as compared to mild cases (8%). Similarly, 75% of patients with mild AP
showed a drop of PCT within the first 48 hours as compared to 50% of patients with moderate and severe cases
(Appendix1).
When subdividing the patients into the 5 possible BISAP score, PCT levels were correlating with severity
from 0 to 2 and to a lesser extent at BISAP 3, however this relation was lost at higher BISAP scores, probably
due to the small number of patients (table 3).
Table 3: Correlation between different BISAP scores and Procalcitonin Levels in Acute Pancreatitis.
Pro-calcitonin
BISAP score (n)
0 (n=10)
1 (n=10)
2 (n=10)
3 (n=6)
4 (n=7)
5 (n=1)
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0.11 (±0.63)
5.00 (±0.63)
19.08 (±33.36)
8.12 (±14.48)
2.05 (±1.72)
15.54 (NA)

p-value

0.010
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There was no correlation between the duration of hospitalization with respect to PCT levels (Figure1).

Fig. 1 Relationship between the duration of hospitalization and PCT levels
Of notice, there is a wide distribution for PCT in BISAP score 2 as compared to BISAP score of 3 and 4
( Figure 2).

Fig. 2 Relationship between Procalcitonin Levels and BISAP score
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4. DISCUSSION:
AP is a serious medical condition that places a considerable burden on the healthcare system. It is of utmost
importance to adequately categorize patients into the various severity classes and to accurately determine the
patients with the worse prognosis in order to manage these cases aggressively and thus reduce the high
mortality rates of such condition. Unfortunately, the scoring systems used at present are often inadequate in
patients with severe AP, which is characterized by rapidly progressive multiple system organ dysfunction.
Therefore, a simple scoring systems or single specific biomarkers that can predict the prognosis of AP are
needed.
Procalcitonin, an early marker of systemic bacterial infection, sepsis, and multiorgan failure, was
introduced as a prognostic marker of AP in the recent years, focusing on systemic inflammation and organ
failure in the early stage of AP (Modrau, 2005). Review of literature about its efficacy revealed some debate
about the role of this biochemical marker as a prognostic factor.One study in 2008 by Gurda-Duda et al.(GurdaDuda, 2008), stated that the early prediction of severe AP was achievable by measuring PCT on admission and
following it up within
48 hours. Subsequent studies have compared the value of serum Procalcitonin to other prognostic markers
such as CRP and Interleukin-6(IL-6) where it showed a higher significance. However, results were variable in
relation to Procalcitonin due to small study sample size and multi-center studies. A Korean study in 2012 by
Kim et al compared the clinical significance between BISAP and PCT. It stated that a BISAP score (≥ 2) was
more accurate (84%) at predicting severity of AP and superior to serum PCT (≥ 3.29 ng/mL, 76% Accuracy)
[10].
In our study, we aimed to study the value of serum Procalcitonin in severity assessment of AP and to
compare it to BISAP. The relation between the absolute quantitative levels of PCT and the severity class was
clear and proportional, denoting a significant additional role that can help in the prognostication of patients
presenting with AP. Although the correlation of the PCT level was less evident with higher BISAP scores,
which is mostly attributed to the very small number of patients having a score of 5 (only 1 patient), the results
shown above suggest a good association with the other BISAP categories. Although current data could not
support the use of PCT alone as a solo test, these findings might support the suggestion that adding PCT levels
to the routine admission panel for such patient will be complementary to the already validated available scores
to improve the prognostication process. Further data is needed in order to integrate the PCT level into the other
scoring systems and develop modified predictive models with higher accuracy and clinical value.Our data also
suggested that serum Procalcitonin is significant in predicting severity of AP at an early stage with cut-off
value of 1.28 (±3.73) ng/ml in mild form of the disease and 4.81 (±6.05) ng/ml for moderate-severe AP (pvalue<0.001). Regarding BISAP, it was evident that the best cutoff score of BISAP was 2 which is similar to
the result stated by Kim et al. [], although some other studies have proposed 3 to be the best cutoff score [].We
aimed to see the relation between the duration of hospitalization with the severity of the disease and found that
patients with severe disease are likely to spend more time in the hospital with an average of 17.11 (±9.40) days
(p-value <0.0001). Beside our primary aim of our study, we noticedthat the use of antibiotics in this study
population was surprisingly very high even in the mild AP group (76.9%). This shows a deficiency in following
the current guidelines [6], which recommend against the routine use of antibiotics in AP except in the case of
severe necrotizing AP (we had only 1 such case in this series) or with the evidence of local infected collections.
Our study had several major limitations. We had only 44 patients over the past 5 years since Procalcitonin
was first introduced to Makassed General Hospital. This was attributed to deficiencies in documentation in our
medical records, the lack of knowledge about the importance of PCT in patients with AP, and the recurrent
occasions of shortage of the laboratory kits supplies. This number is small and a larger number is needed to
provide better results especially in the nigh BISAP score category. We also were not able to compare the PCT
to other predictive models like the Ranson’s criteria and the Balthazar score due to the lack of documentation
in this retrospective study.
5.

CONCLUSION
Serum procalcitonin level is a valuable complementary prognostic marker for assessing the severity of
AP. We suggest to routinely measure and follow-up serial serum PCT levels on patients presenting with AP.
It directly correlates with the three classes of the revised Atlanta classification and best correlates with BISAP
scores of 0 to 3. We suggest a mean cut off value of 2 for denoting a worse prognosis.
Funding: None.
Conflicts of Interest:The authors declare that they have no conflict of interest.
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